Conditional survival of cancer patients: an Australian perspective

BMC Cancer

Xue Qin Yu²  Peter D Baade¹  Dianne L O’Connell³ 

[1] School of Public Health, Queensland University of Technology, Brisbane, Australia

[2] Sydney School of Public Health, The University of Sydney, Sydney, Australia

[3] School of Medicine and Public Health, University of Newcastle, Newcastle, Australia

关键词: Australia;    Cancer registry;    Relative survival;    Conditional survival;   

Others  :  1080149
DOI  :  10.1186/1471-2407-12-460

 received in 2012-08-06, accepted in 2012-09-19,  发布年份 2012

【 摘 要 】

Background

Estimated conditional survival for cancer patients diagnosed at different ages and disease stage provides important information for cancer patients and clinicians in planning follow-up, surveillance and ongoing management.

Methods

Using population-based cancer registry data for New South Wales Australia, we estimated conditional 5-year relative survival for 11 major cancers diagnosed 1972–2006 by time since diagnosis and age and stage at diagnosis.

Results

193,182 cases were included, with the most common cancers being prostate (39,851), female breast (36,585) and colorectal (35,455). Five-year relative survival tended to increase with increasing years already survived and improvement was greatest for cancers with poor prognosis at diagnosis (lung or pancreas) and for those with advanced stage or older age at diagnosis. After surviving 10 years, conditional 5-year survival was over 95% for 6 localised, 6 regional, 3 distant and 3 unknown stage cancers. For the remaining patient groups, conditional 5-year survival ranged from 74% (for distant stage bladder cancer) to 94% (for 4 cancers at different stages), indicating that they continue to have excess mortality 10–15 years after diagnosis.

Conclusion

These data provide important information for cancer patients, based on age and stage at diagnosis, as they continue on their cancer journey. This information may also be used by clinicians as a tool to make more evidence-based decisions regarding follow-up, surveillance, or ongoing management according to patients' changing survival expectations over time.

【 授权许可】

   
2012 Yu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Wang SJ, Wissel AR, Ord CB, Kalpathy-Cramer J, Fuller CD, Holland JM, Gross ND: Individualized estimation of conditional survival for patients with head and neck cancer. Otolaryngol Head Neck Surg 2011, 145(1):71-73.
• [2]Wang SJ, Emery R, Fuller CD, Kim JS, Sittig DF, Thomas CR: Conditional survival in gastric cancer: a SEER database analysis. Gastric Cancer 2007, 10(3):153-158.
• [3]Chang GJ, Hu CY, Eng C, Skibber JM, Rodriguez-Bigas MA: Practical application of a calculator for conditional survival in colon cancer. J Clin Oncol 2009, 27(35):5938-5943.
• [4]Merrill RM, Henson DE, Ries LA: Conditional survival estimates in 34,963 patients with invasive carcinoma of the colon. Dis Colon Rectum 1998, 41(9):1097-1106.
• [5]Zamboni BA, Yothers G, Choi M, Fuller CD, Dignam JJ, Raich PC, Thomas CR Jr, O'Connell MJ, Wolmark N, Wang SJ: Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. J Clin Oncol 2010, 28(15):2544-2548.
• [6]Wang SJ, Wissel AR, Luh JY, Fuller CD, Kalpathy-Cramer J, Thomas CR Jr: An interactive tool for individualized estimation of conditional survival in rectal cancer. Ann Surg Oncol 2011, 18(6):1547-1552.
• [7]Groth SS, Rueth NM, Hodges JS, Habermann EB, Andrade RS, D'Cunha J, Maddaus MA: Conditional cancer-specific versus cardiovascular-specific survival after lobectomy for stage I non-small cell lung cancer. Ann Thorac Surg 2010, 90(2):375-382.
• [8]Skuladottir H, Olsen JH: Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark. J Clin Oncol 2003, 21(16):3035-3040.
• [9]Christensen LH, Engholm G, Ceberg J, Hein S, Perfekt R, Tange UB, Andersson M, Mouridsen HT, Moller T, Storm HH: Can the survival difference between breast cancer patients in Denmark and Sweden 1989 and 1994 be explained by patho-anatomical variables?–a population-based study. Eur J Cancer 2004, 40(8):1233-1243.
• [10]Bowles TL, Xing Y, Hu CY, Mungovan KS, Askew RL, Chang GJ, Gershenwald JE, Lee JE, Mansfield PF, Ross MI, et al.: Conditional survival estimates improve over 5 years for melanoma survivors with node-positive disease. Ann Surg Oncol 2010, 17(8):2015-2023.
• [11]Rueth NM, Groth SS, Tuttle TM, Virnig BA, Al-Refaie WB, Habermann EB: Conditional survival after surgical treatment of melanoma: an analysis of the Surveillance, Epidemiology, and End Results database. Ann Surg Oncol 2010, 17(6):1662-1668.
• [12]Xing Y, Chang GJ, Hu CY, Askew RL, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Cormier JN: Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer 2010, 116(9):2234-2241.
• [13]Baade PD, Youlden DR, Chambers SK: When do I know I am cured? Using conditional estimates to provide better information about cancer survival prospects. Med J Aust 2011, 194(2):73-77.
• [14]Ellison LF, Bryant H, Lockwood G, Shack L: Conditional survival analyses across cancer sites. Health Rep 2011, 22(2):21-25.
• [15]Janssen-Heijnen ML, Gondos A, Bray F, Hakulinen T, Brewster DH, Brenner H, Coebergh JW: Clinical relevance of conditional survival of cancer patients in europe: age-specific analyses of 13 cancers. J Clin Oncol 2010, 28(15):2520-2528.
• [16]Janssen-Heijnen ML, Houterman S, Lemmens VE, Brenner H, Steyerberg EW, Coebergh JW: Prognosis for long-term survivors of cancer. Ann Oncol 2007, 18(8):1408-1413.
• [17]Merrill RM, Hunter BD: Conditional survival among cancer patients in the United States. Oncologist 2010, 15(8):873-882.
• [18]Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, et al.: Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011, 377(9760):127-138.
• [19]Greene FL, Sobin LH: The staging of cancer: a retrospective and prospective appraisal. CA Cancer J Clin 2008, 58(3):180-190.
• [20]AIHW: Cancer in Australia 2001. In vol. Cat. no. CAN 23. Canberra: AIHW; 2004.
• [21]Young J Jr, Roffers S, Ries L, Fritz A, Hurlbut A: SEER Summary Staging Manual - 2000: Codes and Coding Instructions. Bethesda, MD: National Cancer Institute; 2001.
• [22]Greene F, Page D, Fleming I, Fritz A, Balch C, Haller D, Morrow M (Eds): AJCC Cancer Staging Manual. 6th edition. Philadelphia: Springer; 2002.
• [23]Supramaniam R, Smith DP, Coates AS, Armstrong BK: Survival from cancer in New South Wales in 1980 to1995. Sydney: New South Wales Cancer Council; 1999.
• [24]Percy C, Stanek E 3rd, Gloeckler L: Accuracy of cancer death certificates and its effect on cancer mortality statistics. Am J Public Health 1981, 71(3):242-250.
• [25]Berkson J, Gage RP: Calculation of survival rates for cancer. Proc Staff Meet Mayo Clin 1950, 25(11):270-286.
• [26]Brenner H: Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 2002, 360(9340):1131-1135.
• [27]Ederer F, Heise H: Instructions to IMB 650 programmers in processing survival computations. Methodological note No. 10, End Results Evaluation Section. Bethesda: National Cancer Institute; 1959.
• [28]Estimating and modeling relative survival http://www.pauldickman.com/survival/strs.pdf webcite.
• [29]Standard errors of observed and relative survival in strs http://www.pauldickman.com/rsmodel/stata_colon/standard_errors.pdf webcite.
• [30]Ederer F, Axtell LM, Cutler SJ: The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 1961, 6:101-121.
• [31]Hakulinen T: Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics 1982, 38(4):933-942.
• [32]Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R: EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. Eur J Cancer 2009, 45(6):931-991.
• [33]Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, Baili P, Rachet B, Gatta G, Hakulinen T, et al.: Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 2008, 9(8):730-756.
• [34]Cho H, Howlader N, Mariotto AB, Cronin KA: Estimating relative survival for cancer patients from the SEER Program using expected rates based on Ederer I versus Ederer II method. National Cancer Institute; 2011. http://surveillance.cancer.gov/reports/tech2011.01.pdf webcite.
• [35]Hakulinen T, Seppa K, Lambert PC: Choosing the relative survival method for cancer survival estimation. Eur J Cancer 2011, 47(14):2202-2210.
• [36]Perme MP, Stare J, Esteve J: On estimation in relative survival. Biometrics 2012, 68(1):113-120.
• [37]Danieli C, Remontet L, Bossard N, Roche L, Belot A: Estimating net survival: the importance of allowing for informative censoring. Stat Med 2012, 31(8):775-786.